ArticleGynecology and pelvic medicine2025

Atezolizumab with chemotherapy for advanced or recurrent endometrial cancer: does targeting PD-1 or PD-L1 matter in this clinical situation?

Chelsea E Stewart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.